School of Public Health, Dalian Medical University, Dalian, Liaoning, China.
Department of Health Policy and Management, Peking University, Beijing, China.
BMJ Open. 2022 Dec 8;12(12):e066335. doi: 10.1136/bmjopen-2022-066335.
To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019.
Observational study based on the Global Burden of Disease.
The relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI.
Various disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward.
Compared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.
通过全球疾病负担 2019 年(GBD2019)数据库比较亚太国家、中国和全球多发性硬化症疾病指标的负担,并分析 1990 年至 2019 年中国多发性硬化症疾病负担的变化。
基于全球疾病负担的观察性研究。
从 GBD2019 数据库中提取中国、全球和亚太国家多发性硬化症的相关发病率、患病率、死亡率和残疾调整生命年(DALY)率及相应的年龄标准化率(ASR)和社会人口指数(SDI),进一步研究年龄标准化发病率、患病率和死亡率,以及 DALY 率与 SDI 的关系。
中国多发性硬化症的各种疾病负担指标在世界范围内处于较低水平,1990 年至 2019 年期间,患病率、发病率和 DALY 率呈缓慢上升趋势。在此期间,中国多发性硬化症的年龄标准化患病率(ASPR)呈上升趋势,而年龄标准化死亡率(ASDR)、年龄标准化 DALY 率(ASR-DALY)和年龄标准化发病率均呈不同程度的下降,这与全球变化幅度大致一致,且各项指标与亚太地区大多数国家相似。随着 SDI 值的增加,多发性硬化症的 ASPR 呈上升趋势,ASDR 呈下降趋势。
与亚太地区其他国家相比,中国的疾病负担指标处于较低水平。然而,作为一个发展中国家,也是世界上人口最多的国家,患者总数并不小,而且作为一种罕见病,治疗费用相对较高,且疾病引起的并发症的治疗费用也不低。应加强医疗保障体系建设,减轻其给个人、家庭和社会带来的负担。